Dose-response curve of eurycomanone, tamoxifen and vinblastine sulfate against HepG2 cells and WLR-68. Eurycomanone and tamoxifen signifcantly shown a reduced the number of viable malignant HepG2 cells and non-malignant Chang's Liver cells in a dose dependent manner (a). Eurycomanone and vinblastine sulfate also signifcantly shown a reduced the number of viable non-malignant WLR-68 cells in a dose dependent manner (b). The values of graph represent mean ± S.D of three independent experiments. P < 0.05.